High dose Losartan and ACE gene polymorphism in IgA nephritis
Background/aims Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with no...
Gespeichert in:
Veröffentlicht in: | Genomic medicine 2008-12, Vol.2 (3-4), p.83-91 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 91 |
---|---|
container_issue | 3-4 |
container_start_page | 83 |
container_title | Genomic medicine |
container_volume | 2 |
creator | Woo, Keng-Thye Chan, Choong-Meng Choong, Hui-Lin Tan, Han-Kim Foo, Marjorie Lee, Evan J. C. Tan, Chorh-Chuan Lee, Grace S. L. Tan, Seng-Hoe Vathsala, A. Lim, Cheng-Hong Chiang, Gilbert S. C. Fook-Chong, Stephanie Yi, Zhao Tan, H. B. Wong, Kok-Seng |
description | Background/aims
Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day).
Results
Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups (
P
= 0.0005). The loss in eGFR was 0.7 ml min
−1
year
−1
for high dose ARB compared to 3.2–3.5 ml min
−1
year
−1
for the other three groups (
P
= 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (
P
|
doi_str_mv | 10.1007/s11568-009-9030-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2694861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733224259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</originalsourceid><addsrcrecordid>eNp1kUtLAzEYRYMovn-AGwm4cDWadyYLhVJ8QcGNrkOayUwjM8mYtIL_3kiLL3CVwD3fTT4OACcYXWCE5GXGmIu6QkhVClFU1VtgH9cSV1Ixsv11p2wPHOT8ghCXHMldsIcVxUqIeh9c3ftuAZuYHZzFbNLSBGhCAyfTG9i54OAY-_chpnHh8wB9gA_dBAY3LpJf-nwEdlrTZ3e8OQ_B8-3N0_S-mj3ePUwns8rSmtWVssRQ0UjqOFeyMVIg5jBqDVPStsISQShinM-tbUvAWj53SMwplZIbTgQ9BNfr3nE1H1xjXVgm0-sx-cGkdx2N17-T4Be6i2-aCMVqgUvB-aYgxdeVy0s9-Gxd35vg4iprSSkhjHBVyLM_5EtcpVC201hSLJXCnBYKrymbYs7JtV9_wUh_utFrN7q40Z9udF1mTn8u8T2xkVEAsgZyiULn0o-n_239AEb9mEU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1731799153</pqid></control><display><type>article</type><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><source>SpringerLink Journals</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><creator>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</creator><creatorcontrib>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</creatorcontrib><description>Background/aims
Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day).
Results
Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups (
P
= 0.0005). The loss in eGFR was 0.7 ml min
−1
year
−1
for high dose ARB compared to 3.2–3.5 ml min
−1
year
−1
for the other three groups (
P
= 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (
P
< 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria (
P
< 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF (
P
= 0.037).
Conclusion
High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</description><identifier>ISSN: 1871-7934</identifier><identifier>ISSN: 1877-6558</identifier><identifier>EISSN: 1871-7942</identifier><identifier>EISSN: 1877-6566</identifier><identifier>DOI: 10.1007/s11568-009-9030-8</identifier><identifier>PMID: 19319668</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Health Promotion and Disease Prevention ; Human Genetics ; Internal Medicine ; Molecular Medicine ; Public Health ; Research Article</subject><ispartof>Genomic medicine, 2008-12, Vol.2 (3-4), p.83-91</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</citedby><cites>FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694861/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694861/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19319668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Woo, Keng-Thye</creatorcontrib><creatorcontrib>Chan, Choong-Meng</creatorcontrib><creatorcontrib>Choong, Hui-Lin</creatorcontrib><creatorcontrib>Tan, Han-Kim</creatorcontrib><creatorcontrib>Foo, Marjorie</creatorcontrib><creatorcontrib>Lee, Evan J. C.</creatorcontrib><creatorcontrib>Tan, Chorh-Chuan</creatorcontrib><creatorcontrib>Lee, Grace S. L.</creatorcontrib><creatorcontrib>Tan, Seng-Hoe</creatorcontrib><creatorcontrib>Vathsala, A.</creatorcontrib><creatorcontrib>Lim, Cheng-Hong</creatorcontrib><creatorcontrib>Chiang, Gilbert S. C.</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Yi, Zhao</creatorcontrib><creatorcontrib>Tan, H. B.</creatorcontrib><creatorcontrib>Wong, Kok-Seng</creatorcontrib><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><title>Genomic medicine</title><addtitle>HUGO J</addtitle><addtitle>Genomic Med</addtitle><description>Background/aims
Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day).
Results
Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups (
P
= 0.0005). The loss in eGFR was 0.7 ml min
−1
year
−1
for high dose ARB compared to 3.2–3.5 ml min
−1
year
−1
for the other three groups (
P
= 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (
P
< 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria (
P
< 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF (
P
= 0.037).
Conclusion
High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Health Promotion and Disease Prevention</subject><subject>Human Genetics</subject><subject>Internal Medicine</subject><subject>Molecular Medicine</subject><subject>Public Health</subject><subject>Research Article</subject><issn>1871-7934</issn><issn>1877-6558</issn><issn>1871-7942</issn><issn>1877-6566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtLAzEYRYMovn-AGwm4cDWadyYLhVJ8QcGNrkOayUwjM8mYtIL_3kiLL3CVwD3fTT4OACcYXWCE5GXGmIu6QkhVClFU1VtgH9cSV1Ixsv11p2wPHOT8ghCXHMldsIcVxUqIeh9c3ftuAZuYHZzFbNLSBGhCAyfTG9i54OAY-_chpnHh8wB9gA_dBAY3LpJf-nwEdlrTZ3e8OQ_B8-3N0_S-mj3ePUwns8rSmtWVssRQ0UjqOFeyMVIg5jBqDVPStsISQShinM-tbUvAWj53SMwplZIbTgQ9BNfr3nE1H1xjXVgm0-sx-cGkdx2N17-T4Be6i2-aCMVqgUvB-aYgxdeVy0s9-Gxd35vg4iprSSkhjHBVyLM_5EtcpVC201hSLJXCnBYKrymbYs7JtV9_wUh_utFrN7q40Z9udF1mTn8u8T2xkVEAsgZyiULn0o-n_239AEb9mEU</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Woo, Keng-Thye</creator><creator>Chan, Choong-Meng</creator><creator>Choong, Hui-Lin</creator><creator>Tan, Han-Kim</creator><creator>Foo, Marjorie</creator><creator>Lee, Evan J. C.</creator><creator>Tan, Chorh-Chuan</creator><creator>Lee, Grace S. L.</creator><creator>Tan, Seng-Hoe</creator><creator>Vathsala, A.</creator><creator>Lim, Cheng-Hong</creator><creator>Chiang, Gilbert S. C.</creator><creator>Fook-Chong, Stephanie</creator><creator>Yi, Zhao</creator><creator>Tan, H. B.</creator><creator>Wong, Kok-Seng</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Netherlands</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200812</creationdate><title>High dose Losartan and ACE gene polymorphism in IgA nephritis</title><author>Woo, Keng-Thye ; Chan, Choong-Meng ; Choong, Hui-Lin ; Tan, Han-Kim ; Foo, Marjorie ; Lee, Evan J. C. ; Tan, Chorh-Chuan ; Lee, Grace S. L. ; Tan, Seng-Hoe ; Vathsala, A. ; Lim, Cheng-Hong ; Chiang, Gilbert S. C. ; Fook-Chong, Stephanie ; Yi, Zhao ; Tan, H. B. ; Wong, Kok-Seng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3848-9c2a36d73e5597da7604e10fa497cf6c26230455bccf4e14f5be06b33775a5263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Health Promotion and Disease Prevention</topic><topic>Human Genetics</topic><topic>Internal Medicine</topic><topic>Molecular Medicine</topic><topic>Public Health</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Woo, Keng-Thye</creatorcontrib><creatorcontrib>Chan, Choong-Meng</creatorcontrib><creatorcontrib>Choong, Hui-Lin</creatorcontrib><creatorcontrib>Tan, Han-Kim</creatorcontrib><creatorcontrib>Foo, Marjorie</creatorcontrib><creatorcontrib>Lee, Evan J. C.</creatorcontrib><creatorcontrib>Tan, Chorh-Chuan</creatorcontrib><creatorcontrib>Lee, Grace S. L.</creatorcontrib><creatorcontrib>Tan, Seng-Hoe</creatorcontrib><creatorcontrib>Vathsala, A.</creatorcontrib><creatorcontrib>Lim, Cheng-Hong</creatorcontrib><creatorcontrib>Chiang, Gilbert S. C.</creatorcontrib><creatorcontrib>Fook-Chong, Stephanie</creatorcontrib><creatorcontrib>Yi, Zhao</creatorcontrib><creatorcontrib>Tan, H. B.</creatorcontrib><creatorcontrib>Wong, Kok-Seng</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Genomic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Woo, Keng-Thye</au><au>Chan, Choong-Meng</au><au>Choong, Hui-Lin</au><au>Tan, Han-Kim</au><au>Foo, Marjorie</au><au>Lee, Evan J. C.</au><au>Tan, Chorh-Chuan</au><au>Lee, Grace S. L.</au><au>Tan, Seng-Hoe</au><au>Vathsala, A.</au><au>Lim, Cheng-Hong</au><au>Chiang, Gilbert S. C.</au><au>Fook-Chong, Stephanie</au><au>Yi, Zhao</au><au>Tan, H. B.</au><au>Wong, Kok-Seng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High dose Losartan and ACE gene polymorphism in IgA nephritis</atitle><jtitle>Genomic medicine</jtitle><stitle>HUGO J</stitle><addtitle>Genomic Med</addtitle><date>2008-12</date><risdate>2008</risdate><volume>2</volume><issue>3-4</issue><spage>83</spage><epage>91</epage><pages>83-91</pages><issn>1871-7934</issn><issn>1877-6558</issn><eissn>1871-7942</eissn><eissn>1877-6566</eissn><abstract>Background/aims
Several studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day).
Results
Patients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups (
P
= 0.0005). The loss in eGFR was 0.7 ml min
−1
year
−1
for high dose ARB compared to 3.2–3.5 ml min
−1
year
−1
for the other three groups (
P
= 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (
P
< 0.001). Comparing patients with the three ACE genotypes DD, ID and II, all three groups responded well to therapy with decrease in proteinuria (
P
< 0.002). Only those on low dose ACEI (10 mg/day) with the I allele had increased in ESRF (
P
= 0.037).
Conclusion
High dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>19319668</pmid><doi>10.1007/s11568-009-9030-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1871-7934 |
ispartof | Genomic medicine, 2008-12, Vol.2 (3-4), p.83-91 |
issn | 1871-7934 1877-6558 1871-7942 1877-6566 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2694861 |
source | SpringerLink Journals; Springer Nature OA Free Journals; PubMed Central |
subjects | Biomedical and Life Sciences Biomedicine Health Promotion and Disease Prevention Human Genetics Internal Medicine Molecular Medicine Public Health Research Article |
title | High dose Losartan and ACE gene polymorphism in IgA nephritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20dose%20Losartan%20and%20ACE%20gene%20polymorphism%20in%20IgA%20nephritis&rft.jtitle=Genomic%20medicine&rft.au=Woo,%20Keng-Thye&rft.date=2008-12&rft.volume=2&rft.issue=3-4&rft.spage=83&rft.epage=91&rft.pages=83-91&rft.issn=1871-7934&rft.eissn=1871-7942&rft_id=info:doi/10.1007/s11568-009-9030-8&rft_dat=%3Cproquest_pubme%3E733224259%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1731799153&rft_id=info:pmid/19319668&rfr_iscdi=true |